Document is current

Article History

Received: 11 July 2023

Revised: 15 August 2023

Accepted: 28 August 2023

First Online: 15 September 2023

Declarations

:

: The authors declare that they have no conflict of interest.Antemortem human blood were collected from donors in FDA-licensed collection centers located in the USA. All antemortem human blood donors were consented prior to participation and were screened and approved by Innovative Research Inc. (46,430 Peary Court Novi, MI 48377). Postmortem human blood samples were obtained and processed through Discovery Life Sciences Inc. (800 Hudson Way, Suite 1700 Huntsville, AL 35806). Postmortem sites are not required to obtain IRB approval as there is no increased risk to the subject. HHS defines a human subject as a “living individual.” However, consent from either by the subject prior to passing or next of kin postmortem was obtained.All animals were cared for in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the National Institutes of Health (National Academic Press, 1996). The University of Colorado’s Institutional Animal Care and Use Committee (IACUC) approved the CN exposure study (ethics committee: Carter Severance, Genna Nault, Tara Hendry-Hofer, Nathan Wetmore). It complied with the regulations and guidelines of the Animal Welfare Act and the American Association for Accreditation of Laboratory Animal Care.